Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Wilms Tumor × Irinotecan × Clear all

Phase

Phase 2 2 Phase 1 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 33 Pancreatic Neoplasms 16 Colonic Neoplasms 11 Rectal Neoplasms 10 Stomach Neoplasms 9 Neoplasms 9 Small Cell Lung Carcinoma 7 Rhabdomyosarcoma 7 Neuroblastoma 7 Glioblastoma 7 Sarcoma, Ewing 6 Neoplasm Metastasis 6 Central Nervous System Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Glioma 4 Gastrointestinal Neoplasms 4 Brain Neoplasms 4 Advanced Solid Tumors 4 Sarcoma 3 Medulloblastoma 3 Gliosarcoma 3 Digestive System Neoplasms 3 Digestive System Diseases 3 Astrocytoma 3 Recurrence 2 Rectal Diseases 2 Ovarian Neoplasms 2 Osteosarcoma 2 Neoplasms by Site 2 Metastatic Pancreatic Adenocarcinoma 2

Interventions

Temozolomide 3 Filgrastim 2 Drug Therapy 2 talazoparib 1 sargramostim 1 pembrolizumab 1 oblimersen 1 irinotecan sucrosofate 1 etoposide phosphate 1 entrectinib 1 X-Rays 1 Vincristine 1 Specimen Handling 1 Radiotherapy 1 Radiosurgery 1 Proteasome Inhibitors 1 Phantoms, Imaging 1 Peripheral Blood Stem Cell Transplantation 1 Nivolumab 1 Monatide (IMS 3015) 1 Microarray Analysis 1 Lenalidomide 1 Isotretinoin 1 Irinotecan 1 Immunomodulating Agents 1 Immunohistochemistry 1 Ifosfamide 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Etoposide 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05384821 2026-03-18

MetroWilms

Centre Oscar Lambret

Phase 1/2 Recruiting

Kidney Neoplasms, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡